Mitral valve surgery in octogenarians: should we fight for repair? A survival and quality-of-life assessment.

OBJECTIVE: The aim of the study was to evaluate survival and quality of life after mitral surgery in octogenarians. METHODS: From 1987 to 2007, 129 patients ≥ 80 years (median age 82 years; minimum 80 years and maximum 89 years) underwent mitral surgery (87.6% myxomatous, 10% rheumatic, and 2.3% ischemic) with repair procedure in 75 patients and replacement in 54 patients. In the repair and the replacement groups, respectively: Logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) was 5.77 (3.5-63) versus 11.1 (3.5-93.2); and significative preoperative differences were diabetes mellitus (1.3% vs 16.7%, p=0.002) and previous cardiac surgery (0% vs 16.7%, p=0.0001). Survival and quality of life (walking test) were assessed. RESULTS: In the repair and the replacement groups, respectively, hospital mortality (1 month) was 2.7% versus 18.5% (p=0.004). Early (1-6 months) mortality remained high with 9.6% versus 13.6% (p=0.55). Late mortality (6 months-7 years) was stable with an annual mortality of 8% versus 6% per year (p=0.32). The replacement procedure was the only significative predictor of mortality with an odds ratio (OR) of 6.7 (1.1-38.8 (p=0.04)) for operative mortality. Regarding quality of life, with 41 months' (1.1-180) (100%) follow-up, 54.2% (65.9%) of repair (replace) patients were living in a nursing home and walking distance without aid was more than 500 m in 67.1% (81.2%) of patients. CONCLUSIONS: For elderly patients, 6-month mortality better reflects the burden of mitral surgery than the usual 1-month mortality. Even though replacement patients have higher operative estimated risk, mitral replacement remains, after adjustment, an independent predictor of higher operative mortality. Our results claim for wider use of repair technique in mitral surgery for the octogenarians, even if replacement is an acceptable option when repair is technically uncertain.

Anatomic variation: absence of portal vein bifurcation.

PURPOSE: To describe in CT scan the absence of a portal vein bifurcation. METHODS: We described the contrast-enhanced CT scan appearance of an absence of portal vein bifurcation in an "asymptomatic" 39 year old woman. RESULTS: It was a single intrahepatic portal vein which crossed the entire liver parenchyma from the right to the left and with a gradually decreasing diameter. The vascularization of the hepatic parenchyma was not ensured by third order branches, but directly made by second order ramifications which were regularly originated from the single IHPV along its course. This unusual portal vein mimicking a left portal vein agenesis, appeared in fact to be more in relation with a right portal vein agenesis. Distribution of hepatic veins and hepatic volume was normal. CONCLUSION: This very rare anatomic variation is easily detected on CT scan and appears important to describe for surgeon and interventional radiologists.

Long-term outcome after annular mechanical mitral valve replacement in children aged less than five years.

BACKGROUND: When mitral valve repair in children is not possible, mitral valve replacement (MVR) is an alternative, which could result in better outcomes. We report the long-term outcome after replacement of systemic atrioventricular valve with bileaflet mechanical valves in annular position in patients less than 5 years of age. METHODS: Between 1983 and 2008, 29 MVRs were performed in children aged 1.82 ± 1.34 years (range, 95 days to 4.6 years); the average weight was 8.06 ± 2.92 kg (range, 4.7 to 15 kg). The main indication (86%) was severe regurgitation. Prosthesis size ranged between 17 mm and 25 mm. RESULTS: The follow-up was completed and totaled 373 patient-years (12.4 ± 8.6). Four children presented with permanent atrioventricular block. Freedom from thromboembolic and hemorrhage events at 1, 5, 15 years was 100%, 96.1%, and 91.3%, respectively. All deaths occurred within 2 months after MVR and were 5 children (17%). No late mortality was observed. Freedom of redo MVR at 5, 10, and 15 years was 95%, 86%, and 70%, respectively. At MVR, weight 7 kg or less and age 1 year or less (p = 0.03) were associated with redo MVR. During redo MVR, a larger mechanical valve was implanted (+2 sizes), with no postoperative death. Currently, 23 patients are in New York Heart Association class I, and 1 patient is in class II. CONCLUSIONS: The results of mechanical annular MVR are acceptable in children. Anticoagulants are well tolerated, with little thromboembolic complication. Long-term results for patients who survive the hospital period are excellent, and reinterventions show safe results.

Congenital native interruption of aortic arch in an adult: extra-anatomic approach by right-side thoracotomy.

We outline the case of an 18-year-old male patient with a congenital nonoperated interruption of the aortic arch. A right thoracotomy without cardiopulmonary bypass facilitated repair through an extra-anatomic bypass between the ascending and the supradiaphragmatic descending aorta. Results for the immediate and 2-year radiologic and clinical check-up were satisfactory. The most common complications in anatomic correction are stroke under selective cerebral perfusion, risk of paraplegia, and hemorrhage. We present a new technique for repair of interruption of the aortic arch in adults that avoids the need for extended dissection of the aorta and a partial occlusion clamp during anastomosis and allows for cerebral and medullar perfusion.

Intramyocardial Implantation of bone marrow-derived stem cells enhances perfusion in chronic myocardial infarction: dependency on initial perfusion depth and follow-up assessed by gated pinhole SPECT.

UNLABELLED: Cell therapy-induced changes in the perfusion of areas of myocardial infarction (MI) remain unclear. This study investigated whether an original pinhole SPECT technique could be applied to a rat MI model to analyze local improvement in myocardial perfusion relating to engraftment sites of bone marrow-derived stem cells (BMSCs). METHODS: Four-month-old MI rats were either untreated (n = 8) or treated (n = 10) by intramyocardial injection of (111)In-labeled BMSCs. Early distribution of (111)In-BMSCs within the MI target was evidenced by dual (111)In/(99m)Tc pinhole SPECT 48 h later. Myocardial perfusion was serially monitored by (99m)Tc-sestamibi pinhole gated SPECT up to 3 mo after transplantation. RESULTS: Forty-eight hours after transplantation, (111)In-BMSCs were observed in all treated rats and in 18 of their 32 underperfused MI segments (<70% sestamibi uptake before transplantation). During the subsequent 3-mo follow-up, the perfusion of MI segments worsened in untreated rats (absolute change in sestamibi uptake, -3% +/- 3%; P < 0.05) but improved in treated rats (+4% +/- 7%; P < 0.05). This perfusion improvement was unrelated to the initial detection of (111)In-BMSCs (+2% +/- 6% in segments with (111)In-BMSCs vs. +5% +/- 7% in those without; not statistically significant) but was strongly associated with less severe perfusion defects before transplantation (+6% +/- 6% in segments with 60%-70% sestamibi uptake [n = 19] vs. -1% +/- 6% in those with <60% uptake [n = 13]; P = 0.003). CONCLUSION: When BMSCs are injected within chronic MI, perfusion enhancement predominates in the MI areas showing a high enough residual perfusion before treatment but not in those of the initial cell engraftment, giving evidence of dependency on the perfusion and metabolic environment at implantation sites.

Autologous cell based therapy for treating chronic infarct myocardium.

Recent experimental and clinical studies have shown that autologous cell based therapy using skeletal myoblasts or bone marrow-derived stem cells might have beneficial effects in chronic ischemic heart disease. The underlying concept is based on the repopulation of necrotic tissue by either readily contractile myoblasts or by bone marrow-derived stem cells. However, there is a need to resolve a number of issues for determining the better way to perform these treatments and, moreover, for assessing the real beneficial functional effect of each of these cell therapies. In this mini-review, we will discuss (i) the issues of the selection of chronic infarct animal to truly determine the impact of cell therapy on cardiac function recovery, and (ii) the evaluation of the bio-availability and the bio-distribution of transplanted cells. Some new investigational methodologies based on clinical end-points are also proposed.